Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07RMX
|
|||
| Former ID |
DCL000267
|
|||
| Drug Name |
ZK-thiazolidinone
|
|||
| Synonyms |
Zoledronate trisodium; Zoledronate trisodium hydrate; UNII-ARL915IH66; Zoledronate trisodium [USAN]; ARL915IH66; 165800-08-8; Zoledronate trisodium (USAN); CGP-42446B; CGP 42446B; CHEMBL3989655; D06379; Trisodium hydrogen (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonate, hydrate (5:2); Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-, trisodium salt hydrate (5:2)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Preclinical | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bayer Schering Pharma.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H30F3N5O2S
|
|||
| Canonical SMILES |
CCN1C(SC(C1=O)CNC2=CC=CC(=C2)CCN3CCCC3)C(C#N)C(=O)NCC(F)(F)F
|
|||
| InChI |
1S/C23H30F3N5O2S/c1-2-31-21(33)19(34-22(31)18(13-27)20(32)29-15-23(24,25)26)14-28-17-7-5-6-16(12-17)8-11-30-9-3-4-10-30/h5-7,12,18-19,22,28H,2-4,8-11,14-15H2,1H3,(H,29,32)
|
|||
| InChIKey |
WFZRONKPJVZNAO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis. Mol Biol Cell. 2007 October; 18(10): 4024-4036. | |||
| REF 2 | Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. | |||
| REF 3 | Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell. 2007 Oct;18(10):4024-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.